Akebia Therapeutics (AKBA)
0.97
0.00 (0.00%)
Upcoming Events
Latest Headlines
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 1, 2026 4:05 PM - Globe NewsWire
Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
May 28, 2026 8:00 AM - Globe NewsWire
Form SCHEDULE 13G Akebia Therapeutics, Filed by: STATE STREET CORP
May 12, 2026 9:46 AM - SEC Filing
Form 10-Q Akebia Therapeutics, For: Mar 31
May 7, 2026 7:25 AM - SEC Filing
Akebia Therapeutics (AKBA) Misses Q1 EPS by 2c
May 7, 2026 7:08 AM - StreetInsider
Form 8-K Akebia Therapeutics, For: May 07
May 7, 2026 7:06 AM - SEC Filing
Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights
May 7, 2026 7:01 AM - Globe NewsWire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 4, 2026 4:05 PM - Globe NewsWire
Akebia reports vadadustat reduces mortality in kidney disease patients
May 4, 2026 8:04 AM - StreetInsider
Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal
May 4, 2026 8:00 AM - Globe NewsWire
Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights
April 30, 2026 4:06 PM - Globe NewsWire
Form ARS Akebia Therapeutics, For: Dec 31
April 29, 2026 6:05 AM - SEC Filing
Form DEFA14A Akebia Therapeutics,
April 28, 2026 4:14 PM - SEC Filing
Form DEF 14A Akebia Therapeutics, For: Apr 28
April 28, 2026 4:13 PM - SEC Filing
Form PRE 14A Akebia Therapeutics, For: Apr 15
April 15, 2026 4:09 PM - SEC Filing
Leerink Partners on Akebia Therapeutics (AKBA): approval of TVTX's Filspari in FSGS provides positive readthrough
April 14, 2026 10:59 AM - StreetInsider
Akebia begins dosing patients in Phase 1 trial of AKB-9090
April 13, 2026 8:03 AM - StreetInsider
Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090
April 13, 2026 8:00 AM - Globe NewsWire
Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium
April 7, 2026 12:33 PM - Globe NewsWire
H.C. Wainwright Reiterates Buy Rating on Akebia Therapeutics (AKBA)
April 6, 2026 6:53 AM - StreetInsider
Form 4 Akebia Therapeutics, For: Apr 01 Filed by: Vickers Philip J.
April 3, 2026 4:07 PM - SEC Filing
Form 3 Akebia Therapeutics, For: Apr 01 Filed by: Vickers Philip J.
April 3, 2026 4:06 PM - SEC Filing
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 2, 2026 4:05 PM - Globe NewsWire
Form 8-K Akebia Therapeutics, For: Mar 27
April 1, 2026 4:48 PM - SEC Filing
Akebia Therapeutics names Philip Vickers to board of directors
April 1, 2026 4:05 PM - StreetInsider
Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors
April 1, 2026 4:05 PM - Globe NewsWire
Form SCHEDULE 13G/A Akebia Therapeutics, Filed by: VANGUARD GROUP INC
March 26, 2026 3:25 PM - SEC Filing
Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026
March 19, 2026 4:05 PM - Globe NewsWire
Full Article List
